Metabolomics. 2021 Nov 25;17(12):104. doi: 10.1007/s11306-021-01852-w.
Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines.
Metabolomics : Official journal of the Metabolomic Society
Dorna Varshavi, Dorsa Varshavi, Nicola McCarthy, Kirill Veselkov, Hector C Keun, Jeremy R Everett
Affiliations
Affiliations
- Medway Metabonomics Research Group, University of Greenwich, Chatham Maritime, ME4 4TB, Kent, UK.
- Department of Biological Sciences, University of Alberta, 116 Street & 85 Ave, Edmonton, AB, T6G 2R3, Canada.
- Horizon Discovery Ltd., Cambridge Research Park, 8100 Beach Dr, Waterbeach, Cambridge, CB25 9TL, UK.
- Milner Therapeutics Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Puddicombe Way, Cambridge, CB2 0AW, UK.
- Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, SW7 2AZ, UK.
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, W12 ONN, UK.
- Medway Metabonomics Research Group, University of Greenwich, Chatham Maritime, ME4 4TB, Kent, UK. [email protected].
PMID: 34822010
PMCID: PMC8616861 DOI: 10.1007/s11306-021-01852-w
Abstract
INTRODUCTION: KRAS was one of the earliest human oncogenes to be described and is one of the most commonly mutated genes in different human cancers, including colorectal cancer. Despite KRAS mutants being known driver mutations, KRAS has proved difficult to target therapeutically, necessitating a comprehensive understanding of the molecular mechanisms underlying KRAS-driven cellular transformation.
OBJECTIVES: To investigate the metabolic signatures associated with single copy mutant KRAS in isogenic human colorectal cancer cells and to determine what metabolic pathways are affected.
METHODS: Using NMR-based metabonomics, we compared wildtype (WT)-KRAS and mutant KRAS effects on cancer cell metabolism using metabolic profiling of the parental KRAS
RESULTS: Mutation in the KRAS oncogene leads to a general metabolic remodelling to sustain growth and counter stress, including alterations in the metabolism of amino acids and enhanced glutathione biosynthesis. Additionally, we show that KRAS
CONCLUSIONS: Our study showed the effect of a single point mutation in one KRAS allele and KRAS allele loss in an isogenic genetic background, hence avoiding confounding genetic factors. Metabolic differences among different KRAS mutations might play a role in their different responses to anticancer treatments and hence could be exploited as novel metabolic vulnerabilities to develop more effective therapies against oncogenic KRAS.
© 2021. The Author(s).
Keywords: Cells; Colorectal cancer; HCT116; KRAS; Metabolic profiling; Metabolomics; Metabonomics; Mutations; NMR
References
- J Biol Chem. 2013 Jan 25;288(4):2403-13 - PubMed
- Br J Cancer Suppl. 1987 Jun;8:96-104 - PubMed
- Chem Biol Interact. 1998 Apr 24;111-112:213-24 - PubMed
- Nat Genet. 2001 Sep;29(1):25-33 - PubMed
- Mol Cell. 2014 Oct 23;56(2):205-218 - PubMed
- Eur J Clin Invest. 2015 Jan;45 Suppl 1:37-43 - PubMed
- Neoplasia. 2016 Nov;18(11):654-665 - PubMed
- Cell Metab. 2006 Mar;3(3):187-97 - PubMed
- Nat Rev Cancer. 2016 Oct;16(10):650-62 - PubMed
- Pharmacol Ther. 1991;51(2):155-94 - PubMed
- Int J Exp Pathol. 2014 Feb;95(1):8-15 - PubMed
- Oncotarget. 2016 Jul 19;7(29):46717-46733 - PubMed
- Trends Biochem Sci. 2014 Apr;39(4):191-8 - PubMed
- Clin Cancer Res. 2009 Jan 15;15(2):431-40 - PubMed
- Int J Mol Sci. 2012 Sep 25;13(10):12153-68 - PubMed
- Comput Struct Biotechnol J. 2015 Jan 27;13:131-44 - PubMed
- Nature. 2013 Jan 24;493(7433):542-6 - PubMed
- Cancer Cell. 2005 Jan;7(1):77-85 - PubMed
- Metabolomics. 2007 Sep;3(3):211-221 - PubMed
- Cancer Res. 1984 Oct;44(10):4224-32 - PubMed
- Nature. 2012 Nov 15;491(7424):364-73 - PubMed
- Cancer Metab. 2015 Jan 25;3(1):1 - PubMed
- Science. 2012 May 25;336(6084):1040-4 - PubMed
- Mol Cell Oncol. 2014 Oct 29;1(3):e963452 - PubMed
- Nat Med. 1995 Jan;1(1):84-8 - PubMed
- Metabolomics. 2020 Apr 16;16(4):51 - PubMed
- Cancer Cell. 2015 Jan 12;27(1):57-71 - PubMed
- Int J Cancer. 2012 Oct 15;131(8):1810-7 - PubMed
- PLoS One. 2012;7(9):e45190 - PubMed
- Mol Cell. 2014 Nov 6;56(3):414-424 - PubMed
- Anal Bioanal Chem. 2011 Jan;399(3):1127-39 - PubMed
- Cancers (Basel). 2010 Mar 26;2(2):274-304 - PubMed
- Nature. 2016 Mar 3;531(7592):110-3 - PubMed
- Cancer Metab. 2014 Dec 11;2:23 - PubMed
- Crit Rev Clin Lab Sci. 2006;43(2):143-81 - PubMed
- Front Pharmacol. 2014 Aug 26;5:196 - PubMed
- Comput Struct Biotechnol J. 2016 Mar 09;14:135-53 - PubMed
- Trends Pharmacol Sci. 2019 Oct;40(10):763-773 - PubMed
- Hepatology. 2002 Jan;35(1):74-81 - PubMed
- Cell Cycle. 2013 Jul 1;12(13):1987-8 - PubMed
- J Med Life. 2014 Oct-Dec;7(4):581-7 - PubMed
- J Carcinog. 2013 Jun 18;12:9 - PubMed
- Front Mol Biosci. 2018 Apr 09;5:28 - PubMed
- Nature. 2013 Apr 4;496(7443):101-5 - PubMed
- Nat Commun. 2018 Jan 2;9(1):38 - PubMed
- Semin Cell Dev Biol. 2015 Jul;43:22-32 - PubMed
- Cell Metab. 2006 Mar;3(3):177-85 - PubMed
- Nature. 2011 Aug 18;476(7360):346-50 - PubMed
- Science. 2016 Sep 9;353(6304):1161-5 - PubMed
- Cell Rep. 2014 May 22;7(4):1248-58 - PubMed
- Oncogene. 2013 Aug 22;32(34):4028-33 - PubMed
Publication Types